How do people with MS under age 60 compare to those over 60 in terms of occurrence and type of co-morbidities, severity, age of onset, and related factors?
How many people on Tysabri experience a waning effect as they approach their next dose? How much does this effect impact their symptoms and quality of life?
More data/experience on ‘wearing off phenomenon’ with Ocrevus treatment. Can next infusion be administered at 5 months instead of 6 months to avoid this wearing off phenomenon?
Do some MS patients who are/have taken Ocrevus have advancing disability when compared to other medications. In particular gait and mobility issues.
